OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

OS Therapies advances OST-HER2 toward regulatory filings, with key decisions expected in 2027.

What the company is saying

OS Therapies, Inc. is announcing the completion of drug substance requalification for OST-HER2 (Herlystic™), enabling it to proceed with regulatory submissions in the U.S., U.K., and Europe for metastatic osteosarcoma. The company emphasizes the stability of its product, citing data showing critical quality attributes remain intact after ten years in storage. CEO Paul Romness frames this as a major chemistry, manufacturing, and controls milestone, stating the company is now moving aggressively on regulatory fronts. OS Therapies claims it has sufficient funding to operate through mid-2027, supported by a recent capital raise and tax programs, though no specific dollar amounts are disclosed. The company has paused efforts in Australia to focus resources on the U.S., U.K., and Europe. It highlights the potential value of a Priority Review Voucher if BLA approval is achieved, referencing two recent PRV sales totaling $413 million, but caveats that similar outcomes are not guaranteed. The announcement also details regulatory designations and ongoing pipeline activity, but the tone is forward-looking and conditional on future regulatory success.

What the data suggests

The company has completed a technical milestone—requalification of the OST-HER2 drug substance—allowing it to begin regulatory submission processes for Conditional Marketing Authorisation Applications and a Biologics License Application. Stability data confirm the product remains viable after ten years in storage. OS Therapies expects a regulatory decision from the U.K.'s MHRA in Q1 2027 and from the EMA in the first half of 2027, with BLA submission targeted for Q4 2026. The company claims sufficient capital to fund operations through mid-2027, but does not disclose the amount raised or current cash position. The only concrete financial figures are from two recent PRV sales by other parties, totaling $413 million ($206.5 million each), which are used to illustrate potential upside if OS Therapies receives and sells a PRV. OST-HER2 has secured multiple regulatory designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease from the FDA, and Orphan Drug and ATMP from the EMA. The company has completed Phase 2b and Phase 1 trials for OST-HER2 and OST-504, but no new clinical efficacy or safety data are presented in this update.

Analysis

The announcement is upbeat and highlights several regulatory and clinical milestones, but most key claims are forward-looking, such as planned regulatory submissions (CMAA, BLA), anticipated regulatory decisions (MHRA, EMA), and potential future monetization of a Priority Review Voucher. While the completion of drug substance requalification and stability data are realised achievements, the majority of benefits (market access, revenue, PRV sale) are contingent on future regulatory approvals, with decisions not expected until 2027—well over a year away. The company claims sufficient funding through mid-2027, but provides no specific financial figures, and the cited capital raise and tax credits are not quantified. The reference to recent PRV sales is used to imply potential value, but is explicitly caveated as uncertain for OS Therapies. The tone is optimistic and at times promotional, but the actual measurable progress is limited to technical and regulatory enablement steps, not commercial or financial outcomes.

Risk flags

• ●Regulatory approval risk is high, as the company is only now commencing submissions and does not expect decisions until 2027. Delays or negative feedback from regulators could materially impact timelines and prospects.
• ●Financial transparency is limited; while OS Therapies claims funding through mid-2027, it does not disclose the size of its recent capital raise or current cash position, making it difficult to assess the true runway or risk of future dilution.
• ●Commercialization is highly speculative. The company references recent PRV sales totaling $413 million, but explicitly warns there is no assurance it will achieve similar value, and this potential is entirely dependent on successful BLA approval and PRV issuance.
• ●Operational focus has shifted away from Australia, which could limit global market access or signal resource constraints. The company is concentrating efforts on the U.S., U.K., and Europe, potentially narrowing its addressable market.
• ●Pipeline progress for next-generation ADC and DC programs is described in aspirational terms with no disclosed milestones, data, or timelines, increasing uncertainty about the broader portfolio's value.

Bottom line

OS Therapies has achieved a technical milestone with the requalification of its OST-HER2 drug substance, clearing the way for regulatory submissions in major markets. The company is now targeting key regulatory decisions in 2027, but all commercial and financial upside—including the potential sale of a Priority Review Voucher, which has recently fetched $206.5 million per voucher—remains speculative and contingent on future approvals. The claim of sufficient funding through mid-2027 is not backed by specific financial disclosures, leaving the true cash runway unclear. Investors should focus on the actual progress of regulatory submissions and the timing of feedback from the FDA, MHRA, and EMA, as these are the next value-defining events. The most important takeaway is that while technical and regulatory groundwork is advancing, the path to revenue and commercial impact is long and uncertain, with key inflection points still over a year away.

Announcement summary

(NYSE/NASDAQ:OSTX) OS Therapies, Inc. announced the completion of requalification of the drug substance used in its Phase 2b trial of OST-HER2 (Herlystic™) for the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma. This requalification enables the company to begin submission of a Conditional Marketing Authorisation Application (CMAA) and complete a Rolling Review Request for Herlystic (Daznelimgene Lisbac) to the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for early commercial market access, as well as file the Clinical Trial Authorisation (CTA) required to initiate the confirmatory Phase 3 trial. OS Therapies will use the requalification data to support CMAA submissions to the European Medicines Agency (EMA) and to include in the U.S. Food and Drug Administration (FDA) Biologics License Application (BLA) submissions. The company has paused regulatory interactions in Australia to focus resources on the U.S., U.K., and Europe. Paul Romness, Chairman and CEO, stated that the stability data from the Phase 2b trial material shows the product and its Critical Quality Attributes (CQAs) remain stable after ten years in storage. The company reported that its recent capital raise and Refundable R&D Tax Credit and VAT programs provide sufficient resources to fund operations through mid-2027. Due to delays in receiving manufacturing data, OS Therapies now expects a regulatory decision on the pending MHRA CMAA in the first quarter of 2027 and from EMA in the first half of 2027. The company intends to update the market on the timing of completion of BLA activities and related regulatory interactions with the FDA after receiving additional feedback on comparator data for the Accelerated Approval Program. Additional sources of data for OST-400 are being evaluated for inclusion in submissions to the FDA. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD), and Rare Pediatric Disease Designation (RPDD) from the FDA, as well as ODD and Advanced Therapeutic Medicinal Product (ATMP) designation from the EMA. OST-HER2 was granted access to the Centralised Procedure in Europe, allowing for a unified, expedited regulatory review process. Under the RPDD program, if granted a BLA in the U.S., the company would become eligible to receive a Priority Review Voucher (PRV) that it intends to sell. Two recent PRV sales in October 2026 totaled $413 million, with an average of $206.5 million per voucher, though there is no assurance OS Therapies would realize a comparable value. The company has completed resubmission of a Regenerative Medicine Advanced Therapy (RMAT) request and is awaiting FDA feedback. Its Commissioner's National Priority Voucher (CNPV) letter of intent was accepted by the FDA in the first quarter of 2026. OS Therapies intends to complete its BLA submission under the Accelerated Approval Program in the U.S. and CMAAs in Europe and the U.K. for OST-HER2 in metastatic osteosarcoma in the fourth quarter of 2026. OST-HER2 has completed a Phase 1 clinical study in breast cancer patients and showed preclinical efficacy in various breast cancer models. OST-HER2 was previously conditionally approved by the U.S. Department of Agriculture for treating canines with osteosarcoma. The company has completed dosing in a Phase 1 study of OST-504 for castration-resistant prostate cancer. OS Therapies is also advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which uses proprietary silicon Si-Linker and Conditionally Active Payload (CAP) technology to deliver multiple payloads per linker.

Disagree with this article?